Liposomal oral formulations offer 50-90% bioavailability with convenient home administration
HaCaT keratinocytes have also been proven to be good candidates for assessing skin irritancy and toxicity in conventional monolayer assays measuring using MTT reduction as the viability endpoint 21
This is most relevant for weight-based peptides like kisspeptin (dosed in mcg/kg) and less relevant for receptor-saturating peptides like BPC-157, where tissue concentration at the injury site matters more than total body distribution
As of April 2026, the BPC-157 FDA approval status remains what it has been for the last two decades: no finished-drug approval, no active Investigational New Drug (IND) application, and no FDA-registered human clinical trials
Here's how it typically unfolds: Your complexion becomes more even as your liver gets better at processing toxins (thanks, glutathione!)
Glutathione also protects your mitochondria, promoting cell energy production